Evofem Biosciences (EVFM)
(Delayed Data from OTC)
$0.01 USD
0.00 (-4.21%)
Updated Sep 13, 2024 03:38 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Evofem Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 4 | 13 | 71 | 24 |
Receivables | 6 | 1 | 6 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 5 | 8 | 7 | 0 |
Other Current Assets | 1 | 2 | 3 | 18 | 2 |
Total Current Assets | 9 | 13 | 30 | 98 | 26 |
Net Property & Equipment | 1 | 4 | 6 | 4 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 4 | 1 | 1 | 1 |
Total Assets | 11 | 25 | 43 | 110 | 28 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 43 | 66 | 109 | 52 | 0 |
Accounts Payable | 17 | 15 | 10 | 11 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 6 | 13 | 11 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5 | 5 | 3 | 1 | 0 |
Total Current Liabilities | 72 | 94 | 138 | 77 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 25 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 72 | 97 | 142 | 109 | 13 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 5 | 0 | 5 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 823 | 817 | 751 | 657 | 529 |
Retained Earnings | -889 | -939 | -861 | -655 | -513 |
Other Equity | -1 | 50 | 5 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -62 | -72 | -100 | 1 | 16 |
Total Liabilities & Shareholder's Equity | 11 | 25 | 43 | 110 | 28 |
Total Common Equity | -67 | -72 | -104 | 1 | 16 |
Shares Outstanding | 25.10 | 1.10 | 0.00 | 0.00 | 0.00 |
Book Value Per Share | -2.65 | -65.27 | -104.32 | 1.35 | 15.64 |
Fiscal Year End for Evofem Biosciences, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 1 | 1 | 0 | 1 |
Receivables | 5 | 4 | 6 | 6 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 2 | 3 | 4 |
Other Current Assets | 1 | 1 | 1 | 2 | 3 |
Total Current Assets | 7 | 7 | 9 | 12 | 12 |
Net Property & Equipment | 1 | 1 | 1 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 9 | 8 | 11 | 13 | 14 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 43 | 42 | 43 | 41 | 43 |
Accounts Payable | 16 | 16 | 17 | 16 | 17 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 8 | 7 | 7 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6 | 8 | 5 | 4 | 4 |
Total Current Liabilities | 73 | 74 | 72 | 68 | 70 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 73 | 74 | 72 | 68 | 70 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 5 | 5 | 5 | 2 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 824 | 823 | 823 | 829 | 821 |
Retained Earnings | -892 | -894 | -889 | -885 | -950 |
Other Equity | -1 | -1 | -1 | 0 | 73 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -65 | -66 | -62 | -55 | -56 |
Total Liabilities & Shareholder's Equity | 9 | 8 | 11 | 13 | 14 |
Total Common Equity | -69 | -71 | -67 | -56 | -56 |
Shares Outstanding | 100.30 | 59.40 | 25.10 | 9.40 | 3.60 |
Book Value Per Share | -0.69 | -1.19 | -2.65 | -6.00 | -15.46 |